Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALB stock price vs CPB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CPB's multiple
Needs CPB P/S.
Implied fair value · at ALB's multiple
Needs ALB P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALBEMARLE CORPORATION · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
The Campbell’s Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
FMC CORP
ALB vs FMC
CHEMICAL & MINING CO OF CHILE INC
ALB vs SQM
Avalo Therapeutics, Inc.
ALB vs AVTX
LITHIUM AMERICAS CORP.
ALB vs LAC
RPM INTERNATIONAL INC/DE/
ALB vs RPM
PPG INDUSTRIES INC
ALB vs PPG
COCA COLA CO
ALB vs KO
PEPSICO INC
ALB vs PEP
Keysight Technologies, Inc.
ALB vs KEYS
Mondelez International, Inc.
ALB vs MDLZ
J M SMUCKER Co
ALB vs SJM
Lamb Weston Holdings, Inc.
ALB vs LW
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ALB can rapidly restore positive margins and earnings growth from its current -7.1% operating margin and -4.4% revenue growth, then a contrarian buy could make sense; otherwise, the data support avoiding or underweighting ALB because it is priced far above both CPB-implied valuation and the DCF range despite weaker fundamentals than CPB.
ALB trades at a steep premium to CPB despite materially weaker operating performance, with the provided P/S-based implied price of $28.99 versus the current price of $125.60, implying 76.9% downside. ALB is also above the top of its historical band and well above the DCF range, indicating the market is pricing in a recovery that the current financials do not yet justify.
Supporting Metrics
